Immunovia AB (publ)
IMMVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $931 | $1,575 | $1,145 | $844 |
| % Growth | -40.9% | 37.6% | 35.7% | – |
| Cost of Goods Sold | $0 | $6,682 | $4,211 | -$14,969 |
| Gross Profit | $931 | -$5,107 | -$3,066 | $15,813 |
| % Margin | 100% | -324.3% | -267.8% | 1,873.6% |
| R&D Expenses | $0 | $0 | $4,575 | $4,734 |
| G&A Expenses | $0 | $0 | $0 | $82,607 |
| SG&A Expenses | $94,475 | $182,874 | -$4,575 | $82,607 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $15,867 | $108,479 | $0 | $0 |
| Operating Expenses | $110,342 | $291,353 | $188,143 | $182,554 |
| Operating Income | -$109,411 | -$296,460 | -$191,150 | -$166,628 |
| % Margin | -11,752% | -18,822.9% | -16,694.3% | -19,742.7% |
| Other Income/Exp. Net | $32,870 | -$12,979 | $23,058 | $10,662 |
| Pre-Tax Income | -$76,541 | -$309,439 | -$168,092 | -$155,966 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$76,541 | -$309,439 | -$168,092 | -$155,966 |
| % Margin | -8,221.4% | -19,646.9% | -14,680.5% | -18,479.4% |
| EPS | -0.93 | -7.95 | -6.89 | -6.4 |
| % Growth | 88.3% | -15.4% | -7.7% | – |
| EPS Diluted | -0.93 | -7.95 | -6.89 | -6.4 |
| Weighted Avg Shares Out | 82,614 | 38,923 | 24,386 | 24,386 |
| Weighted Avg Shares Out Dil | 82,614 | 38,931 | 24,386 | 24,386 |
| Supplemental Information | – | – | – | – |
| Interest Income | $34,730 | $6,283 | $745 | $710 |
| Interest Expense | $1,860 | $1,166 | $1,600 | $1,432 |
| Depreciation & Amortization | $13,416 | $141,719 | $24,913 | $19,063 |
| EBITDA | -$61,265 | -$148,462 | -$141,579 | -$135,471 |
| % Margin | -6,580.6% | -9,426.2% | -12,365% | -16,051.1% |